Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: Long-term efficacy and safety results from 2 randomized phase-III studies and 1 open-label long-term extension study.

Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: Long-term efficacy and safety results from 2 randomized phase-III studies and 1 open-label long-term extension study.

Item
http://www.wikidata.org/entity/Q39980767
JAK-STAT Signaling as a Target for Inflammatory and Autoimmune Diseases: Current and Future Prospects.The Future of Janus Kinase Inhibitors in Inflammatory Bowel Disease.Recent Advances in Small Molecule and Biological Therapeutic Approaches in the Treatment of Psoriasis.Secukinumab for the treatment of psoriatic arthritis.Therapeutic Potential of Targeting the Th17/Treg Axis in Autoimmune Disorders.Janus kinase (JAK) inhibitors for the treatment of skin and hair disorders: a review of literature.JAK inhibitors in dermatology: The promise of a new drug class.Tofacitinib for the treatment of moderate to severe chronic plaque psoriasis in Japanese patients: Subgroup analyses from a randomized, placebo-controlled phase 3 trial.Tofacitinib for induction and maintenance therapy of Crohn's disease: results of two phase IIb randomised placebo-controlled trials.The expanding therapeutic armamentarium for inflammatory bowel disease: how to choose the right drug(s) for our patients?Efficacy and safety of tofacitinib for moderate-to-severe plaque psoriasis: a systematic review and meta-analysis of randomized controlled trials.Tofacitinib: A New Oral Therapy for Psoriasis.Exome-wide association study reveals novel psoriasis susceptibility locus at TNFSF15 and rare protective alleles in genes contributing to type I IFN signalling.Malignancy Risk and Recurrence with Psoriasis and its Treatments: A Concise Update.Molecular Mechanisms and Management of a Cutaneous Inflammatory Disorder: Psoriasis.Advances in treating psoriasis in the elderly with small molecule inhibitors.Tofacitinib induction and maintenance therapy in East Asian patients with active ulcerative colitis: subgroup analyses from three phase 3 multinational studies.
P2860

Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: Long-term efficacy and safety results from 2 randomized phase-III studies and 1 open-label long-term extension study.

Item
http://www.wikidata.org/entity/Q39980767
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh
2016年學術文章
@zh-hant
name
Tofacitinib, an oral Janus kin ...... bel long-term extension study.
@en
Tofacitinib, an oral Janus kin ...... bel long-term extension study.
@nl
type
label
Tofacitinib, an oral Janus kin ...... bel long-term extension study.
@en
Tofacitinib, an oral Janus kin ...... bel long-term extension study.
@nl
prefLabel
Tofacitinib, an oral Janus kin ...... bel long-term extension study.
@en
Tofacitinib, an oral Janus kin ...... bel long-term extension study.
@nl
P1433
P1476
P2093
P304
P31
P356
P407
P433
P478
P50
P577
P5875
P698
P356
P1433
P1476
Tofacitinib, an oral Janus kin ...... bel long-term extension study.
@en
P2093
P304
P31
P356
10.1016/J.JAAD.2016.01.013
P407
P433
P478
P50
P577
P5875
P698